Avalo Therapeutics (AVTX) Research & Development (2014 - 2026)

Avalo Therapeutics has reported Research & Development for 13 years, with the latest figure at $14.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 53.97% year-over-year to $14.0 million; the trailing twelve-month figure through Mar 2026 stood at $55.0 million (up 74.94% YoY), and the FY2025 full-year result was $50.1 million, up 104.95% from the prior year.
• Research & Development for Q1 2026 stood at $14.0 million, up from $13.3 million in the prior quarter.
• The five-year high for Research & Development was $14.1 million in Q2 2025, with the low at $1.2 million in Q3 2023.
• Historically, Research & Development has averaged $7.9 million across 5 years, with a median of $8.2 million in 2024.
• Annual changes were most pronounced in 2023 — Research & Development plunged 82.26% — and 2024, when it soared 663.65%.
• Avalo Therapeutics' Research & Development stood at $6.2 million in 2022, then tumbled by 69.75% to $1.9 million in 2023, then jumped by 338.3% to $8.2 million in 2024, then surged by 62.13% to $13.3 million in 2025, then increased by 5.88% to $14.0 million in 2026.
• The last three Research & Development figures came in at $14.0 million (Q1 2026), $13.3 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.